{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05881369",
            "orgStudyIdInfo": {
                "id": "91257336"
            },
            "organization": {
                "fullName": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Examining Clinical Research Participation for Substance Abuse Disorder Patient",
            "officialTitle": "Exploring the Clinical Trial Journey of Patients in Substance Abuse Disorder Clinical Trials",
            "therapeuticArea": [
                "Other"
            ],
            "study": "examining-clinical-research-participation-for-substance-abuse-disorder-patient"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-19",
            "studyFirstSubmitQcDate": "2023-05-19",
            "studyFirstPostDateStruct": {
                "date": "2023-05-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-19",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Clinical study participation percentages haven't always been fully representative of a given demographic.\n\nThe goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through.\n\nThe data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future substance abuse disorder patients during clinical trials."
        },
        "conditionsModule": {
            "conditions": [
                "Substance Abuse Disorder"
            ],
            "keywords": [
                "substance abuse disorder"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_CROSSOVER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Rate of patients who decide to enroll in a substance abuse disorder clinical study.",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Number of substance abuse disorder patients who remain in clinical trial until completion.",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \u2265 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.\n* Participant has a diagnosis of substance abuse disorder.\n* Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n\nExclusion Criteria:\n\n* Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.\n* Pregnant or lactating woman\n* Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Substance abuse disorder patients who are actively considering involvement in an observational clinical trial, but have not yet completed enrollment and registration.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael B Gill",
                    "role": "CONTACT",
                    "phone": "415-900-4227",
                    "email": "bask@withpower.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael B Gill",
                    "affiliation": "Power Life Sciences Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Power Life Sciences",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael B Gill",
                            "role": "CONTACT",
                            "phone": "415-900-4227",
                            "email": "https://www.withpower.com/contact-us@withpower.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "35012793",
                    "type": "BACKGROUND",
                    "citation": "Kock P, Froelich K, Walter M, Lang U, Dursteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30."
                },
                {
                    "pmid": "32690036",
                    "type": "BACKGROUND",
                    "citation": "Jaguga F, Kwobah E. A review of the public sector substance use disorder treatment and prevention systems in Kenya. Subst Abuse Treat Prev Policy. 2020 Jul 20;15(1):47. doi: 10.1186/s13011-020-00291-5."
                },
                {
                    "pmid": "21907503",
                    "type": "BACKGROUND",
                    "citation": "Tull MT, Gratz KL. The impact of borderline personality disorder on residential substance abuse treatment dropout among men. Drug Alcohol Depend. 2012 Feb 1;121(1-2):97-102. doi: 10.1016/j.drugalcdep.2011.08.014. Epub 2011 Sep 9."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-05-19",
                    "uploadDate": "2023-05-19T10:09",
                    "filename": "ICF_000.pdf",
                    "size": 72185
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Substance Abuse",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}